<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="United States), 1000 units/mL of penicillin, and 100 μg/mL of" exact="streptomycin" post="(Invitrogen, Carlsbad, CA, United States). Infections were performed in"/>
 <result pre="Figure 2A, at a concentration of 12.5 μM, corilagin and" exact="ellagic acid" post="showed about 40% inhibition, while CHLA, CHLI, and 1,2,3,4,6-pentagalloyllucose"/>
 <result pre="CHLI, and 1,2,3,4,6-pentagalloyllucose (PGG) showed &amp;gt; 90% inhibition. Since corilagin," exact="ellagic acid," post="and PGG have been well characterized for their antiviral"/>
 <result pre="virus release in a dose-dependent manner, like the positive control" exact="oseltamivir" post="phosphate (Figure 4A). FIGURE 4 CHLA and CHLI block"/>
 <result pre="potency of CHLA and CHLI with the marketed NA inhibitor" exact="oseltamivir" post="carboxylate, a yield reduction assay was performed with six"/>
 <result pre="CHLI (1.58 μM) upon A/H1N1/PR8 were lower than that of" exact="oseltamivir" post="carboxylate (3.92 μM), suggesting their comparable activities (Figure 5A)."/>
 <result pre="CHLI (Figures 5D,E).Interestingly, NA/H274Y in A/H1N1/pdm(09) virus conferred resistance to" exact="oseltamivir" post="carboxylate, but the potency of CHLA and CHLI was"/>
 <result pre="FIGURE 5 Dose–response curves of CHLA, CHLI, and reference compound" exact="oseltamivir" post="acid against virus replication in a yield reduction assay."/>
 <result pre="for the prophylaxis and treatment of influenza virus infections, including" exact="oseltamivir" post="(Shobugawa et al., 2012), zanamivir (von Itzstein et al.,"/>
 <result pre="of influenza virus infections, including oseltamivir (Shobugawa et al., 2012)," exact="zanamivir" post="(von Itzstein et al., 1993), peramivir (Alame et al.,"/>
 <result pre="(Shobugawa et al., 2012), zanamivir (von Itzstein et al., 1993)," exact="peramivir" post="(Alame et al., 2016), and laninamivir (Kashiwagi et al.,"/>
 <result pre="2016), and laninamivir (Kashiwagi et al., 2016). Among these drugs," exact="oseltamivir" post="remains a first-line therapy since it was approved in"/>
 <result pre="therapy since it was approved in 1999. However, resistance to" exact="oseltamivir" post="has constantly been reported due to its wide use"/>
 <result pre="NAs (Li et al., 2010; Air, 2012). Upon binding of" exact="oseltamivir" post="or zanamivir, the open 150-loop of group 1 NAs"/>
 <result pre="a deficient 150-cavity in its crystal structure, conferring resistance to" exact="oseltamivir" post="(Li et al., 2010). In addition, another auxiliary binding"/>
 <result pre="G.Rocha Crispino SantosM. A.Alves da CunhaA. J. (2014). Amantadine and" exact="rimantadine" post="for influenza A in children and the elderly.Cochrane Database"/>
 <result pre="activity of strictinin from Pu′er tea after thermal degradation to" exact="ellagic acid" post="and gallic acid.J. Food Drug Anal.23116–123. 10.1016/j.jfda.2014.07.00728911434 ColmanP. M."/>
</results>
